Drug Discovery: Meet the DIANA Technology
Experience the future of drug discovery with DIANA (DNA-linked Inhibitor ANtibody Assay), an ultra-sensitive multi-well plate based protein detection assay, cost effective and highly sensitive solution for different drug discovery services!
Discover the advantages of the DIANA Technology with our DIANA Kinase Panel and DIANA CDK Panel, two innovative drug discovery technologies designed for your exact needs. The DIANA CDK Panel offers selectivity profiling against 25 Cyclin Dependent Kinases (CDKs) with high sensitivity and a wide dynamic range, ensuring reliable enzyme inhibition constant (Ki) determination from a single well. Complementing this, the DIANA Kinase Panel provides comprehensive profiling of target inhibitors across the kinome, featuring low reaction volumes and minimal antibody consumption, all within a multi-well plate format. Both panels enable high throughput screening, making them indispensable tools for advancing your drug discovery projects with precision and efficiency.
How does it work?
DIANA is a multi-well plate assay, where target protein is selectively captured to the solid carrier and then bound by a unique detection probe consisting of a small-molecule ligand linked to a DNA-oligonucleotide. Subsequently, the probe is detected and quantified by qPCR. For drug discovery, the assay utilizes competition between the probe and the test compounds to measure their binding affinity, so it is becoming a straightforward tool to develop new targets.
DIANA Kinase Panel
- Selectivity profiling of target inhibitors against the kinome.
- Based on a novel DIANA
(DNA-linked Inhibitor ANtibody Assay). Ultrasensitive tool with a wide dynamic range. - Reliable determination of enzyme inhibition constants (Ki) from a single well.
- Low reaction volume (5 µL), and low antibodies/ antigens consumption due to multi-well plate format.
- High throughput screening possible with any assay in our portfolio.
DIANA CDK Panel
- Selectivity profiling of target compounds against the 25 Cyclin Dependent Kinases (CDKs).
- Based on a novel DIANA (DNA-linked Inhibitor ANtibody Assay). Ultrasensitive tool with a wide dynamic range.
- Determination of enzyme inhibition constants (Ki) on multi- well plate format.
- Reliable Ki determination from a single well.
DIANA technology - Products & services
Our robust pipeline showcases our commitment to advancing drug discovery with a range of highly validated assays. The most important include validated and licensable assays for CDK Panel and Kinase Panel. We also developed assays for Prostate Specific Membrane Antigen (PSMA/GCPII), Glutamate Carboxypeptidase III (GCPIII), Carbonic Anhydrases (with panels for 11 isoforms, IX and XII), and Fibroblast Activation Protein (FAP). Additionally, we offer specialized assays for Influenza Neuraminidase N1 and we have begun the development of Methyl Transferases detection assay. Each target has undergone thorough development, with probes synthesized and tested to ensure the highest quality and reliability for your research needs.
Check the table above for the details and do not hesitate to contact us to discuss your project needs.
| Target | Development status | Products available | |||
| Development initiated | Probe synthesized & tested | Assay validated - available for licensing | Screening assay | Detection assay |
|
| DIANA Kinase Panel | YES | YES | |||
| DIANA CDK Panel | YES | YES | |||
| Carbonic anhydrases panel (11 isoforms) | YES | ||||
| Methyl transferases | |||||
| Prostate specific membrane antigen (PSMA/GCPII) | YES | YES | |||
| Glutamate Carboxypeptidase III (GCPIII) | YES | ||||
| Carbonic anhydrases IX and XII | YES | YES | |||
| Fibroblast activation protein (FAP) | YES | YES | |||
| Influenza Neuraminidase N1 | YES | ||||
Scientific presentations
Development of new methods for detection of respiratory viruses
We were presenting the new methods for detection of respiratory viruses at “Pečenkovy epidemiologické dny” in Plzeň at 14th-16th April 2022.
Meet DIANA at ECBS/LS-EuChemS in Madrid
We are presenting the DIANA platform at 6th European Chemical Biology Symposium and the meeting of the EuChemS Division “Chemistry in Life Sciences” in Madrid at 3rd-5th April 2019. Meet us there to learn about DIANA’s potential in HTS screening and affinity profiling of Carbonic anhydrase inhibitors and discuss partnership opportunities.
Meet DIANA at SLAS 2019 in Washington DC
We are presenting DIANA at SLAS 2019 in Washington DC 4th-6th February 2019. Meet us there to learn about DIANA’s potential in HTS screening and affinity profiling and discuss partnership opportunities.
DIANA used to identify inhibitors of influenza neuraminidase
The team of scientists at IOCB successfully used DIANA technology to screen for inhibitors of influenza neuraminidase. Their study has been published in Biochemical Journal. Kožíšek et al. (2019): DNA-linked inhibitor antibody assay (DIANA) as a new method for screening influenza neuraminidase inhibitors.
DIANA-based research papers
DIANA for drug discovery – High Throughput Screening leading to rapid identification of novel leads.
Methodology paper in preparation
Kožíšek et al. (2019): DNA-linked inhibitor antibody assay (DIANA) as a new method for screening influenza neuraminidase inhibitors.
Navratil et al. (2017): DIANA for sensitive and selective enzyme detection and inhibitor screening. Nucleic Acids research.
Are you interested in our technology? Contact our team of experts!
Jan Tykvart
Head of Research and Development
